Introduction {#s1}
============

The global prevalence of diabetes mellitus among adults over 18 years of age is expected to increase from 4.4% in 1980 to 8.8% in 2017 ([@B21]; [@B18]). Type 2 diabetes mellitus (T2DM) represents 90% of diagnosed cases of diabetes and represents a potential global epidemic ([@B18]). The prevalence of T2DM is increasing and is likely to affect 500 million people worldwide by 2030 with up to 1 in 8 adults suffering from the disease ([@B18]). Affordability and availability of medicines are growing challenges for healthcare systems all over the world ([@B40]). In developing countries, the expenditure on medicines represents 25--66% of the total public and private health spending, and hence accounts for the biggest household expense after food ([@B41]).

Globally, spending on diabetes medicines by healthcare systems and individuals has increased and this represents a significant proportion of healthcare budgets ([@B40]). The new insulin analogues and oral diabetes medicines have been associated with high expenditures, both for individuals and governments ([@B6]) and the cost of these medicines are considered a major challenge in accessing these medicines particularly in low- and middle-income countries (LMICs) ([@B22]).

For the past 40 years, the World Health Organization (WHO) has been at the forefront of promoting equality in access to medicines in high-income countries and LMICs. Based on efficacy, safety, and affordability of medicines the WHO has developed an essential medicine list (EML). The medicines on this list are defined as: "*...those that satisfy the priority health care needs of the population*" ([@B41]). Some high-income countries have also introduced mechanisms to improve medicines access such as wise list in Stockholm, Sweden, with initially just 200 plus medicines for ambulatory care (now expanded to include hospital outpatients) developed on the premise that most physicians only know 200 to 300 medicines well ([@B15]). As a specialized agency concerned with international public health, World Health Organization/Health Action International (WHO/HAI) have been working in the last decade or so to collect evidence to measure and promote affordability and availability of medicines, particularly in LMICs ([@B13]; [@B23]; [@B7]; [@B37]; [@B24]; [@B9]; [@B25]; [@B38]; [@B4]).

Recent research suggests that a month's treatment with oral diabetes medicines is available at low cost in middle- and high-income countries ([@B7]; [@B9]; [@B23]). Across LMICs, a growing body of literature has evaluated the availability and prices of diabetes medicines ([@B2]; [@B7]; [@B9]; [@B38]; [@B42]) but the prices reported in these studies may not reflect what patients and governments are actually paying for these medicines. However, some recent studies did explore the availability and affordability of essential medicines to treat non-communicable diseases ([@B10]; [@B38]; [@B6]).

Unaffordable medicine prices and poor availability are among many factors that affect access to medicines ([@B28]). Low availability and low affordability of medicines have the potential to affect a significant proportion of the world population. Low availability of medicines can be due to several factors such as high prices, poor prescribing practices of both innovator brands and generics, ineffective supply systems, and lack of patient compliance ([@B23]). Evidence shows that about half of the population in the poorest parts (such as in China) cannot afford essential medicines, mainly due to the high or unaffordable costs ([@B28]). More than 95% of the drugs on WHO EML are no longer patented however it is estimated that a large number of people still do not have regular access to medicines ([@B44]; [@B10]; [@B6]). This means a gap in the access to medicine exists. It is also important to emphasize that a low procurement price does not always translate into a low cost to the patient.

In this context, the aim of this study was to measure availability, pricing, and affordability of four essential diabetes medicines in private primary care pharmacies in 17 low-, middle, and high-income countries. Measuring the prices and availability of medicines will contribute toward an enhanced understanding of actual prices patient pays at private sector retail pharmacies, and affordability of essential medicines for diabetes treatment. Informed prices would allow government and funding agencies to negotiate prices with pharmaceutical companies ([@B44]; [@B7]).

Methods {#s2}
=======

Sampling Strategy {#s2_1}
-----------------

A survey was conducted to examine the availability, pricing, and affordability of selected essential diabetes medicines. Low- and middle-income countries were the target countries for this study. A purposive sampling method was used to collect data ([@B16]). The surveyed countries were categorized into four groups. The World Bank income group 2018 was used to define the income status of each of the chosen countries ([@B32]; [@B33]; [@B34]; [@B35]).

Data Collection and Survey Tool {#s2_2}
-------------------------------

A data collection form was adapted from WHO/HAI standard methods measuring the price and availability of selected diabetes medicines ([@B44]; [@B16]). The developed data collection form had three sub sections; the first section was on demographics of the country, the second section was on the medicine outlet, and last section was on medicine prices and availability of four medicines where the international reference prices (IRP) were available; metformin 500 mg, metformin 850 XR, gliclazide 80 mg, and insulin 100 IU/ml. These products were selected based on our consultation with the collaborators in sampled countries.

Data were collected between March and June 2018. The project described in an invitation letter was emailed to selected individuals and groups (academics, pharmacists, and other healthcare professionals). In case no response was received following the initial email, a follow-up email was sent 2 weeks later. When written consent for participation was received, another email was sent with the data collection tool and supplementary information including data collection information sheets, and a final checklist. The "checklist" specified that by providing the requested data consent was deemed to be given by the data collector. Data collectors were provided written instructions on how to collect data. All data collectors were given the option to contact a team member to go through the data collection process.

Data were collected by making one visit to at least two private primary care pharmacies in the capital or main city in each participating country. Each data collector was instructed to collect pharmacy level prices for each of the four selected medicines for innovator brand (IB) and lowest priced generic (LPG) ([**Table 1**](#T1){ref-type="table"}). The price and availability of each medicine was recorded using the provided data collection forms. Furthermore, the national currency, exchange rate expressed in US dollars on the day of data collection along with daily wage of the lowest-paid unskilled government worker was recorded.

###### 

Four essential medicines used to treat diabetes included in the survey.

  Medicine name           Brand          Indication   Medicine strength   Dosage Form         WHO essential medicine list
  ----------------------- -------------- ------------ ------------------- ------------------- --------------------------------------------------------------------------------------------------------------------------
  Metformin               Glucophage     Diabetes     500 mg              Tablet or capsule   On the WHO core list in the same dosage form and strength On the WHO complementary list in same dosage form and strength
  Metformin XR            Glucophage     Diabetes     850 mg XR           Tablet or capsule   On the WHO list in different dosage form or strength
  Gliclazide              Diamicron      Diabetes     80 mg               Tablet or capsule   On the WHO core list in the same dosage form and strength
  Insulin human soluble   Novo Nordisk   Diabetes     100 IU/ml           Injection           On the WHO core list in the same dosage form and strength

Upon receipt of data it was screened for completeness and accuracy. This was achieved by checking the brand names of the IB as manufacturers do not use the same trading names across countries. Brand names for the IB were checked and accepted as appropriate. Currency exchange and wages of the lowest-paid unskilled government workers were double checked by the authors. In cases where data was missing or unclear the data collector was contacted for clarification.

Availability Assessment {#s2_3}
-----------------------

In each surveyed facility the availability of IB and lowest priced generic were recorded for the selected medicines using Microsoft^®^ Excel. The availability was recorded as being i) available on survey date or ii) not available on survey date, regardless of the available pack size. Differences in availability between innovator and generic product of a given medicine on its own and the mean availability will determine if the availability differs significantly. The availability in each facility was described using the following range ([@B13]): very low (≤30), low ([@B31]; [@B19]; [@B30]; [@B3]; [@B36]; [@B45]; [@B5]; [@B11]; [@B20]; [@B27]; [@B39]), fairly high (50--80), and high (≥80). For each medicine it was recorded if the medicine was listed on the WHO EML ([**Table 1**](#T1){ref-type="table"}).

Price-Ratio Comparison {#s2_4}
----------------------

The WHO/HAI methods for comparison of local prices with supplier median unit price (USD) listed in Management Sciences for Health's Drug Price Indicator Guide was adapted for this study ([@B26]). Where no median supplier prices were available, the listed buyer median unit prices were used. A median price ration (MPR) for each country was calculated using the lowest generic prices for each medicine. The IRP is an indicator for how costly the medicine is. If the calculated ratio is ≤1 the reported price is considered to be reasonable in public sector. A value ≥3 in the private sector means the local's pay more for the medicine than recommended by WHO ([@B44]; [@B16]).

Affordability Assessment {#s2_5}
------------------------

The affordability of each medicine was calculated for each country separately using the price of the lowest priced medicine irrespective of brand. The estimate is based on the number of days wages, the lowest-paid unskilled government worker would require to purchase 30 days of treatment at a standard dose. The WHO recommends that for a treatment to be affordable it should not exceed 1 day's wages using the wage of the lowest-paid unskilled government worker. It is important to note that the estimate is based on if the patient were to pay for the treatment out-of-pocket and thus other arrangements such as private insurance and government funding has not been considered in this estimate.

Currency Conversion {#s2_6}
-------------------

The prices of IBs from local currencies were converted to US\$ using both foreign exchange rates and purchasing power parity (PPP). In foreign exchange rates method, we used the foreign exchange rates (FOREX) on September 24^th^, 2018 to perform the conversion ([@B12]). In PPP, we used PPP rates provided by the World Bank to perform the conversion ([@B43]). Rates for PPP are estimated based on the cost of purchasing a similar basket of goods in different countries. Unlike FOREX, PPP values do not fluctuate significantly with time ([@B30]).

Statistical Analysis {#s2_7}
--------------------

The data were analyzed using SPSS version 24 with 0.05 as level of significance. The price-ratio, availability, and affordability were presented as means and standard deviations. The differences in price-ratio and affordability between countries grouped into four categories based on their income level were calculated using Kruskal-Wallis test and Mann-Whitney for pairwise comparisons.

Results {#s3}
=======

Out of 50 countries approached, 20 (40.0 percent) agreed to participate and provided the data in the study. The surveyed countries were Oman, Qatar, Saudi Arabia, United Arab Emirates, China, Jordan, Russia, Armenia, Bangladesh, Egypt, Georgia, India, Pakistan, Sri Lanka, Afghanistan, Nepal, and Tanzania. Of 20 countries, data collection forms from 3 countries were excluded due to inadequate data set.

Surveyed Primary Care Pharmacies {#s3_1}
--------------------------------

Using a standardized approach, the availability of medicines in 51 primary care pharmacies across seventeen countries were surveyed. [**Table 2**](#T2){ref-type="table"} shows the countries where the survey samples were successfully collected along with their WHO region and income level.

###### 

Countries included in the survey.

  Country                WHO regions             Income level ([@B33]; [@B34]; [@B35]; [@B26])   Surveyed pharmacies per country
  ---------------------- ----------------------- ----------------------------------------------- ---------------------------------
  Afghanistan            Eastern Mediterranean   Low income                                      3
  Armenia                Europe                  Lower middle income                             3
  Bangladesh             South-East Asia         Lower middle income                             3
  China                  Western Pacific         Upper middle income                             3
  Egypt                  Eastern Mediterranean   Lower middle income                             2
  Georgia                Europe                  Lower middle income                             3
  India                  South-East Asia         Lower middle income                             2
  Jordan                 Eastern Mediterranean   Upper middle income                             3
  Nepal                  South-East Asia         Low income                                      3
  Oman                   Eastern Mediterranean   High income                                     3
  Pakistan               Eastern Mediterranean   Lower middle income                             3
  Qatar                  Eastern Mediterranean   High income                                     2
  Russia                 Europe                  Upper middle income                             3
  Saudi Arabia           Eastern Mediterranean   High income                                     4
  Sri Lanka              South-East Asia         Lower middle income                             3
  Tanzania               Africa                  Low income                                      3
  United Arab Emirates   Eastern Mediterranean   High income                                     3

Availability of Medicines {#s3_2}
-------------------------

The total mean availability of four medicines (IBs and LPGs) on the day of the survey was lowest in Georgia (29%) and highest in Pakistan (88%) as presented in [**Table 3**](#T3){ref-type="table"}. No IBs (of four surveyed medicines) were available in Bangladesh and Nepal. The total mean percentage availability of IBs was very low (≤30%) in Armenia, Egypt, India, and Tanzania. For LPGs, only two countries (Georgia and Saudi Arabia) had total mean percentage availability less than 30%.

###### 

Median percentage availability of selected diabetes medicines in each country and mean percentage availability of innovator brand and lowest priced generic in each country

  Medicines                                   Afghanistan   Armenia   Bangladesh   China   Egypt   Georgia   India   Jordan   Nepal   Oman   Pakistan   Qatar   Russia   Saudi Arabia   Sri Lanka   Tanzania   United Arab Emirates   Total mean percentage availability   
  ------------------------------------------- ------------- --------- ------------ ------- ------- --------- ------- -------- ------- ------ ---------- ------- -------- -------------- ----------- ---------- ---------------------- ------------------------------------ ----
  Metformin 500 mg                            IB            100       100          0       33      33        100     0        100     0      100        100     100      100            100         67         33                     100                                  69
  LPG                                         100           100       100          100     33      100       66      66       100     100    100        100     100      100            50          100        100                    100                                  89
  Metformin 850 mg XR                         IB            67        0            0       0       0         33      0        0       0      33         0       0        100            50          33         0                      0                                    19
  LPG                                         33            33        0            100     33      100       33      67       0       100    66         100     33       100            0           33         100                    0                                    53
  Gliclazide 80 mg                            IB            0         0            0       67      33        0       0        0       0      0          100     33       0              50          67         0                      0                                    21
  LPG                                         0             0         20           100     67      100       0       67       0       100    100        100     33       0              0           100        0                      0                                    46
  Insulin 100 IU/ml                           IB            33        0            0       67      0         0       100      100     0      0          100     100      33             50          100        100                    67                                   50
  LPG                                         0             0         40           0       33      0         0       50       100     0      0          100     0        0              25          33         0                      0                                    26
  Total mean percentage availability          42            33        38           42      46      29        44      50       38      50     88         50      54       41             63          38         50                                                          
  Total mean percentage availability of IB    50            25        0            42      17      33        25      50       0       33     75         58      58       63             67          25         50                                                          
  Total mean percentage availability of LPG   33            40        75           42      75      25        63      50       75      67     100        42      50       19             58          50         50                                                          

≤30, very low; 30--49, low; 50--80, fairly high; ≥80, high.

The total mean availability of insulin 100 IU/ml was 36.21% (IBs and LPGs), with the branded product (50% total mean availability) of insulin 100 IU/ml more frequently available than LPG (26% total mean availability) across 17 surveyed countries. LPG of insulin was not available in 10 out of 17 surveyed countries on the day of survey. Both IB and LPG of insulin were not available in Bangladesh, Egypt, Georgia, Nepal, Oman on the day of the survey. The total availability of IBs was particularly low for metformin 850 XR (19%) and gliclazide 80 mg (21%). The total availability of LPGs was also low for insulin 100 IU/ml (26%). There was a high mean availability of metformin 500 mg (89% of LPG *vs*. 69% of IB) across all income levels.

Affordability of Medicines {#s3_3}
--------------------------

The affordability of 30-day treatment of each medicine was calculated using the minimum wage for the lowest-paid unskilled government worker in each country. Thirty-day treatment of all the medicines were affordable in most of the surveyed countries except in few countries in low-income group like Tanzania ([**Table 4**](#T4){ref-type="table"}). For 1 month's treatment with metformin 500 mg (twice a day for 30 days), patients would have to spend more than 5 day's wages for the IB and 2.5 day's wages for LPG in Tanzania. Conversely, for the same medicine, patients would have to spend ≤0.5 day's wages in middle- and high-income countries. In case of affordability, significant difference was noted between regional groupings for IB insulin 100 IU/ml, where a significant difference was observed between low-income and high-income countries (2.37 *vs*. 0.46, *p = 0.038*) suggesting that IB insulin 100 IU/ml is more affordable in high-income compared to low-income countries.

###### 

Affordability and median price-ratio comparisons for selected medicines, innovator brand, and their equivalent generic, by income level.

  Medicines             Lower income   Lower-middle income   Upper-middle income   High income                                   
  --------------------- -------------- --------------------- --------------------- ------------- ------ ------ ---------- ------ ----------
  Metformin 500 mg      IB             **2.63**              **3.15**              0.32          1.82   0.52   6.60       0.29   **3.50**
  LPG                                  0.88                  1.17                  0.27          1.89   0.28   **3.52**   0.11   1.65
  Metformin 850 mg XR   IB             0.06                  0.38                  0.33          2.19   0.25   **3.23**   0.11   **7.26**
  LPG                                  0.52                  1.18                  0.26          2.12   0.13   2.06       0.10   0.70
  Gliclazide 80 mg      IB             --                    --                    0.44          0.64   0.04   2.82       0.02   3.85
  LPG                                  0.01                  0.10                  0.23          0.80   0.04   2.98       0.03   2.75
  Insulin 100 IU/ml     IB             **2.37**              0.58                  0.12          2.16   0.29   0.75       0.46   0.92
  LPG                   --             --                    --                    0.12          2.36   0.07   1.21       0.02   0.20

For median price-ratio, a value ≥3 in the private sector means the local's pay more for the medicine than recommended by WHO \[22, 29\]. The WHO recommend that for a treatment to be affordable it should not exceed 1 day's wages using the wage of the lowest-paid unskilled government worker. Bolded figures show price-ratio more than WHO recommended value of ≥3 in the private sector OR when figure exceeded 1 day's wages. Bolded figures represents statistical significance = p \< 0.05.

Prices of Medicines {#s3_4}
-------------------

Overall, IBs were more expensive than LPGs but not in all cases ([**Table 4**](#T4){ref-type="table"}). For example, the price for IB of metformin 500 mg was less than the prices of LPG in facilities in Afghanistan, Armenia, Egypt, Georgia, and Saudi Arabia. This was also the case for insulin 100 units/ml in Jordan and Oman.

The MPRs for insulin 100 IU/ml (IB and LPG) were found to be higher in low and lower-middle income countries. For insulin 100 IU/ml, countries in low-income paid 2.37 times the IRP while countries in high-income group paid only 0.92 times the IRP to procure IB.

In the present study, it has been found that countries paid 0.10 to 7.26 times the IPRs to procure surveyed medicines. The MPR for IB metformin 500 mg was higher in upper-middle- and high-income countries than low- and lower-income countries. Countries in upper-middle and high-income paid 6.60 and 3.50 times the IRP to procure IB of metformin 500 mg, respectively. In case of LPG metformin 500 mg, MRP was highest in upper middle-income countries (countries in this group paid 3.52 times the IRP to LPG of metformin 500 mg).

The MPR for gliclazide 80 mg (IB and LPG) were found to be higher in upper middle- and high-income countries compared with low-income countries. For example, countries in lower-middle income paid 0.44 times the IRP to procure IB of gliclazide while countries in high-income group paid 3.85 times the IRP. In pairwise comparisons, statistically significant differences in median price ratios between income levels were only noted for Diamicron (gliclazide 80 mg) (p = 0.007).

[**Table 5**](#T5){ref-type="table"} presents foreign exchange rates and PPP adjusted median prices for 30-days treatment with IBs. When using foreign exchange rates, the median drug price of insulin 100 IU/ml was highest in the Oman (\$4.82) and for the remaining six countries, the range of median prices was from \$0.043 to \$2.52. When using purchasing power parity to convert from local currency to US\$, the pattern of prices was different. The highest PPP-adjusted price for insulin 100 IU/ml was in Bangladesh (\$80.21). Both, Sri Lanka (\$30.50) and India (\$30.79) had similar PPP adjusted median prices for insulin. The PPP-adjusted prices for metformin 500 mg was highest in Tanzania (\$4334.17) followed by Armenia (\$1479.87).

###### 

Median prices for 30-days treatment with diabetes medicines, by foreign exchange rates, and purchasing power parity adjustment.

  Countries                  Metformin 500 mg   Metformin 850 XR   Gliclazide 80 mg   Insulin 100 IU/ml                 
  -------------------------- ------------------ ------------------ ------------------ ------------------- ------ ------ -------
  **Afghanistan**            1.92               40.28              --                 --                  --     --     --
  **Armenia**                7.38               1479.87            --                 --                  --     --     --
  **Bangladesh**             4.31               137.18             4.32               137.63              2.52   2.52   80.21
  **Egypt**                  1.07               3.64               0.67               2.29                0.71   0.71   2.44
  **Georgia**                5.76               5.64               --                 --                  --     --     --
  **India**                  0.02               0.39               2.38               42.92               1.71   1.71   30.79
  **Jordan**                 4.23               1.35               --                 --                  --     --     --
  **Nepal**                  0.39               13.39              0.15               5.25                0.04   0.04   1.49
  **Oman**                   2.79               0.45               2.16               0.34                4.82   4.82   0.77
  **Pakistan**               0.83               25.71              0.73               22.79               0.88   0.88   27.18
  **Qatar**                  4.53               8.48               --                 --                  --     --     --
  **Russia**                 2.26               52.99              2.54               59.59               --     --     --
  **Saudi Arabia**           201.60             306.43             --                 --                  --     --     --
  **Sri Lanka**              0.44               21.88              --                 --                  0.61   0.61   30.50
  **Tanzania**               5.93               4334.17            5.27               3852.59             --     --     --
  **United Arab Emirates**   1.76               0.04               --                 --                  --     --     --

\*XR, price in US\$ when converted from local currency using foreign exchange rates.

\*\*PPP, price in US\$ when converted from local currency using purchasing power parity.

Discussion {#s4}
==========

The present study compared the availability, prices, and affordability of four diabetes medicines across 17 countries. Medicines used to treat diabetes are listed on the WHO EML but the access to these medicines is still a worldwide concern. In the majority of lower- and middle-income countries the private sector retail pharmacies are the preferred place to buy medicines. One of the reasons for this trend is that these have a higher availability than public pharmacies, and often also more accessible in terms of geographical location ([@B31]). Our findings are similar to previous findings on chronic conditions in low- and middle-income countries ([@B31]; [@B23]; [@B7]; [@B38]). Generally, LPGs are more readily available than IBs. For instance, India and neighboring countries had more LPGs than IBs available ([@B19]; [@B38]). This is not surprising as India has a high production of generic medicines. We suggest that governments should be looking at policies to enhance the routine availability of low cost good quality generics (and in the long term striving for Universal Health Coverage) in growing areas of concern including hypertension and type 2 diabetes.

Compared to previously conducted studies not much improvement in availability has been observed. [@B10] performed the secondary analysis of 30 surveys undertaken in low-income and middle-income countries from 2008 to early 2015 using the WHO/HAI methodology. They reported median percentage availability (in private sector for any diabetes product) of 69.5% (IBs: 12.1% and LPGs: 65.2%) in low-income, 71.0% (IBs: 24.0%, LPGs: 66.2%) in lower- and middle-income, and 89.9% (IBs: 60.0%, LPGs: 71.7%) in upper-middle income countries ([@B10]). The median percentage availability of LPGs of metformin (500 and 850 mg) and insulin 100 IU/ml was lower in present study compared with previous studies as shown in [**Table 6**](#T6){ref-type="table"}.

###### 

Comparison of availability of diabetes medicines.

  Medicines                                                    Availability of LPGs (No. of studies)^a^   Current study
  ------------------------------------------------------------ ------------------------------------------ ---------------
  Metformin 500 and 850 mg cap/tab                             76.7% (n = 23)                             70.97%
  Insulin human, soluble, isophane and 30/70, 100 IU/ml vial   30.0% (n = 9)                              26.0%
  Gliclazide 80 mg cap/tab                                     13.3% (n = 4)                              46.0%

Ewen M, Zweekhorst M, Regeer B, Laing R (2017) Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS ONE 12(2): e0171284.

Given the low mean availability of medicines in LMICs measures must be taken to increase the availability ([@B3]; [@B36]; [@B11]). The analysis of availability of a given medicine is important when laying the strategy to implement easy and affordable access to medicines. For example, factors contributing to poor availability of insulin such as its quantification at the national level, in-country distribution, and determination of needs at lower levels of the health system should be addressed to improve insulin availability ([@B5]). Beran *et al*., argued that very little has been done globally to address the issue of access, despite the United Nation's political commitment ([@B5]). Previous literature from the Jiangsu province in China showed implementation of national policies to have a positive impact on the availability ([@B45]).

Significant differences were observed in the prices of surveyed medicines in low-, middle-, and high-income countries (using foreign exchange rates and PPP adjusted). The differences in prices of IBs obtained using foreign exchange rates and PPP adjustment were significant in low- and middle-income countries (e.g., in Armenia and Tanzania), while these differences were insignificant in high-income countries (e.g., Oman and Qatar). One of the main reasons is the difference in the value of US currency between the countries.

On the international market, the diabetes medicines are available at relatively low costs; for example, the median monthly treatment costs in 2015 were US\$ 0.50 for gliclazide 80 mg, US\$ 1.94 for metformin, and US\$ 4.35 for regular or neutral protamine Hagedorn insulin ([@B39]). In this study, most of the surveyed countries had higher monthly treatment costs for metformin and gliclazide and lower monthly treatment costs for insulin than international market. One approach to improve affordability could be increasing the availability of low cost metformin and low cost biosimilar insulins which can help address the growing burden of diabetes across countries.

The present study found that the prices of 30-day insulin 100 IU/ml treatment vary across countries ([**Figure 1**](#f1){ref-type="fig"}). A parallel pattern of varied insulin prices is observed in previous studies ([@B5]; [@B20]). Insulin was found to be more affordable in middle- and high-income countries than low-income countries. One study in Hubei province in China found that at least four day's wages were required to pay for 1-month treatment with insulin 100 IU/ml (Human Regular) ([@B20]). Novo Nordisk, a lead insulin manufacturer, have developed a differential pricing mechanism in order to increase affordability of insulin ([@B27]). To combat the difference in price it has been suggested that the WHO establish a drug information facility which would report on price, safety, effectiveness, and quality-assurance of essential medicines ([@B5]). The literature also suggests, substantially higher prices of new insulin analogues and diabetes medicines and their additional costs to individuals. These systems need to be assessed in terms of added clinical benefit and financial impact ([@B13]; [@B5]).

![Median prices of 30-day insulin treatment (Human Regular Insulin 100 IU) prices for Innovator Brand and Lowest Prices Generic expressed in US\$ across 13 countries.](fphar-10-01375-g001){#f1}

In this study, median number of day's wages needed to procure IBs and LPGs of four surveyed diabetes medicines were 1.69 and 0.47 in low-income; 0.30 and 0.22 in lower-middle income; and 0.27 and 0.13 in upper-middle income countries. Median number of days' wages needed to purchase standard diabetes treatments with IBs and LPGs elsewhere were 5.3 and 1.1 in low-income, 3.8 and 1.4 in lower-middle income, 1.4 and 0.5 in upper-middle income countries ([@B5]; [@B10]).

Tanzania is one country in this study, where we found very low median percentage availability of surveyed medicines and 1-month's treatment with metformin 500 mg (twice a day for 30 days) costs more than 5 day's wages for the IB and 2.5 day's wages for LPG. This could be due to selection of EM or lack of economic evaluations when listing medicines. Mori and colleagues ([@B25]) report on how the selection of EMs in Tanzania is based on the committees of experts' experience and discretionary judgment rather than evidence-based research. The authors found that low availability of pharmacoeconomic studies in Tanzania could be one reason for this trend as well as lack of training in evidence-based decision-making.

As reported by [@B10], one of the goals for Global Action Plan for the Prevention and Control of NCDs 2013--2020 (GAP) was to improve patient access to affordable medicines. They underline the importance of increased commitment and national interventions in order for the project to be successful. They also found that there was a low availability and/or affordability of essential medicines. Most often the medicines are not available in the public sector, which forces the patients to seek the private sector.

Enforcing national policies and recommendations for pro-generic prescribing could encounter the low or no availability of essential medicines. Generally, the use of generic medicines provides cheaper alternate options and lower the expenditure for patients who are paying out-of-pocket. However, generic medicines often cost more than 2 to 3 times the IRP in the public sector due to manufacturers' selling prices, taxes, and mark-up in the supply chain ([@B7]). Some LPGs were found to be costlier than the corresponding IB in this study.

Hassali and colleagues reviewed experiences with successful implementation of generic substitution in eight selected countries ([@B17]). Among others they found that some generic medicines are priced more than expected or original brand medicines in some countries ([@B17]).

It is important to understand that there are different policies implemented to promote generic medicines, for example, generic substitution in the US, generic prescribing in the UK, and mandatory generic substitution in Sweden and Finland ([@B17]). One important factor that play a role is perceptions of healthcare professional and patients. Previous studies show that although the use of generic medicines is more affordable, but patients and healthcare professionals hold negative perceptions regarding the use of generic medicines ([@B29]; [@B17]; [@B8]). An understanding of their perceptions and attitudes toward the use of generic medicines would allow for a more cost-effective use of medicines ([@B29]; [@B8]). Healthcare professionals also play a vital role in educating patients about generic medicines through counseling and educational campaigns.

Recently, Department of Health in Abu Dhabi, United Arab Emirates has authorized generic prescribing as first choice of dispensing ([@B1]; [@B14]). If the patient wants the higher priced original brand, they can buy this by paying for the difference between the lowest generic and innovator. This model is also used in high-income countries in Europe e.g., Denmark, Sweden, and Finland.

Limitations and Recommendations for Future Studies {#s4_1}
--------------------------------------------------

This study has a number of limitations. First, data were collected for few strengths of the three diabetes essential medicines only. Second, this is a point-in-time sampling study and data were only collected from at least two private retail pharmacy sites per country (range: 2 --4), therefore the results are less generalizable than if multiple sites were sampled within countries. Third, as we have applied purposive sampling, countries with active collaborations with authors were more likely to be sampled than those who did not, and therefore might have introduced selection bias. It would have been better if more countries from sub-Saharan Africa, South America had taken part with an appreciable and growing prevalence of diabetes (principally T2DM).

Fourth, the study did not capture the data about level of patient co-payment for oral anti-diabetic medicines or educational input prescribers receive to help make sense of the findings as there can be high prices---but this is not an issue in LMICs with universal access since in these countries medicines are provided free of charge in government facilities. The real issues are adherence to medicines once prescribed and ensuring their availability in primary healthcare centers (as this can necessitate purchasing directly from community pharmacies). Also, we did not explore the concerns with generics in these countries including issues of quality.

Fifth, a diverse definition of "availability" used across studies. The WHO/HAI standardized method calls for using specific strength and dosage form as indicated in collection forms. This methodology is not always followed, some studies define a medicine to be available regardless of the available IB/generic and in some cases also strength of the medicine ([@B9]; [@B17]). A more rigid approach to the definition of availability would allow to track trends over time and hence identify which essential medicine are available at which strength and price.

Sixth, the definition of "selling price" varies across studies. Many studies including current study do not take mark-ups, taxes, and other distribution costs under consideration when calculating and comparing prices. For future studies it would be essential to include a measure of the weakness in the supply system to identify action required to increase the availability and affordability of EM.

Finally, there are limitations that are inherent from WHO/HAI's methodology. For example, this study has used the wage of lowest-paid unskilled government worker to calculate affordability. There may be individuals who earn less and hence data may not be a true reflection of the reality ([@B44]; [@B7]). Incorporate other living fixed costs such as food, electricity, water, home rent when measuring affordability. Leading medicine and pharmaceutical pricing researchers have proposed an alternative metric to express affordability, but this is not yet readily used.

Conclusions {#s5}
===========

Overall the availability of four essential diabetes medicines was found to be sub-optimal in the primary care pharmacy settings. Across the 17 countries, some facilities did not have any branded products available. Although the availability of the generic form of insulin was found to be poor, we also found a lower monthly treatment cost compared to the international market. The four medicines have an acceptable median price-ratio and affordability in most of the surveyed countries. There is a need to move from *ad hoc* study culture to studies that follow standardized methodologies to support evidence-based decision-making.
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